TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Stage 2 Duration of Labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Cesarian Section
Endpoint domain: Adverse events/effects
Primary endpoint: Average Apgar Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of oxaliplatin
Endpoint domain: Adverse events/effects
Primary endpoint: Anatomic success of rectocele repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of All-cause hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of All-cause deaths
Endpoint domain: Mortality/survival
Primary endpoint: Minimum effective volume of bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of reported cases of uveitis
Endpoint domain: Adverse events/effects
Primary endpoint: Immune Response Measured by IFN-gamma Secreting PBMC Precursor Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Adverse Events Graded Using NCI CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Confirmed to Have Switched From Cigarettes to Halo G6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of the gene therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Inhibition Index (MI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toe Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Glasgow Coma Score (GCS) < 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Access to treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Wender Reimherr Adult Attention Deficit Disorder Scale (WRAADDS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change from baseline in patient reported outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change from baseline in bleeding assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: EEG change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ABG change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in scores of attention test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of plantar foot diabetic ulcer recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of bleeding and cramping days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Usability of the method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Cellular Infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of alarms per patient-day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Umbilical Artery Blood Gas Analysis - pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Umbilical Artery Serum Lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Newborn Apgar Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of S. aureus surgical site infections (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Exhaled Levels of Nitric Oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean total daily OFF time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Urine Albumin to Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relative change in frequency of hot flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MADRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of convective removal of protein-bound solutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Role of diffusion and convection in removal of protein-bound uremic toxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Clinical Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Provocative Concentration of Methacholine Causing a 20% Fall in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time of first occurrence and recurrence of clinical features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with at least one clinical feature and highest severity grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life measured by EORTC QLQ C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life (QOL) measured by EuroQol EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Technical performance of Tc-99m tetrofosmin SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median change in Glasgow Coma Scale (GCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: height (for BMI calculation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: questionnaire and scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Red-cell transfusion packs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 8-Week Disease Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of PSP following Sternotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Infants With a HR ≥ 100 Bpm at 2 Minutes of Life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Remain in place
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful implantation of the WATCHMAN device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of life-threatening events
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of FACBC PET and PEM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 24-hour ambulatory systolic and diastolic blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Marginal bone remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decrease of Vital Capacity and Forced Volume Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease of the 6-Minute Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoracoabdominal mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Creatinine (mg/dL) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Baseline in GFR (ml/min/1.73m2) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maintenance of Change in Insomnia Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Serum 25-hydroxy vitamin-D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EEG patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rapid Eye Movement (REM) motor disinhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects experiencing dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Attaining NCEP LDL-C Target at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Attaining NCEP LDL-C Target at Week 44
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coronary artery disease demonstrated by coronary angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inflammatory marker (TREM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of Cmax of BI 409306 in CSF Compared to Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Change From Baseline of cGMP in CSF Calculated as Ratio (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum (Absolute) Change From Baseline of cGMP Concentration in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Operation Related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge regarding spontaneous abortion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude towards spontaneous abortion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Practices regarding spontaneous abortion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under GIR-curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to maximal glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to first hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTX1 change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CO confirmed continuous abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient clinical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Low Back Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants developing contrast-induced nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pathology Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change of the MADRS Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in grey-scale (GS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in power Doppler (PD) semi-quantitative scores from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of subjects of tomograms analyzed by AI techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with similarity results of tomogram interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of treatment related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of abnormal lab findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant vitamin A stores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Enrolled Participants with Data Collection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Median Number of Cycles Monitored
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in venipuncture pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Physical Activity Levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: QoR40
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: cGVHD Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle stretch reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tendon tap reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: consumption of fentanyl citrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in 6-min-walk test distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responses of the McAllinden and Metamorphopsia Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Maximum Voluntary Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Negative Inspiratory Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in neurological classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With No Vomiting Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Cobb Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Thoracic Spine Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Space Available for Lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of Procedure-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Total-group Response Rate at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Related Systemic Adverse Events (Excluding Infections)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Related Systemic Adverse Events (Excluding Infections) Per Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Change in Total Clinical Score (TCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of discontinuation of anesthetic to eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of discontinuation of anesthetic to tidal volume (TV) 300ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of discontinuation of anesthetic to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Detection Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Grade 3 or 4 Hematologic Toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: frequency of grade 3 treatment related toxicities or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Change in KAH Score for Children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pathological reclassification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Static balance control in reaction to perturbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic balance control in reaction to perturbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of interscalene nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rates of HIV acquisition
Endpoint domain: Mortality/survival
Primary endpoint: Rates of STD acquisition
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Subjects with Antibody Concentration ≥ 0.2 μg/mL for Pneumococcal Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects with Antibody Concentration ≥ 0.2 μg/mL for Anti-19A Pneumococcal Serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects with Antibody Concentration ≥ 0.2 μg/mL for Anti-6A and 19A Pneumococcal Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose of T-regulatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Quality of Life (QoL) at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical Healing of anal fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Toxicity of PS-341 combined with thalidomide
Endpoint domain: Adverse events/effects
Primary endpoint: 30% Prostate specific antigen (PSA) decline within 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of High Dose Carfilzomib
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of High Dose Carfilzomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of symptom score of functional dyspepsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI (psoriasis area and severity index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLQI (dermatology life quality index)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hospital length-of-stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Physical neurological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Montreal Cognitive Assessment (MoCA) Taiwan Version
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Digit Span Task-forward (DS-forward)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Color Trails Test-2 (CTT-2)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Stroop Color Word Test (SCWT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Nine Hole Peg Test (NHPT)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline Get-Up and Go Test (GUG)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the 21-item Hamilton Depression Rating Scale (HDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Pertinent Ocular Adverse Events (POAEs) Per Injection
Endpoint domain: Adverse events/effects
Primary endpoint: significant weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduced risk of diabetes and heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total pathological complete response rate (tpCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change of pain WOMAC subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of WON
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cerebral oxygenation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Completion of developmental evaluation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Eligibility determination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of genomic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of immunologic biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Residual Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New onset AFACS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in atrial fibrillation/atrial flutter burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of cerebral infarcts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic performance of CT-LSIM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in motivation to quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in stages of changes to quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing